HT-101 monotherapy with 2 injections achieves surface antigen (HBsAg) seroconversion in 48 weeks! Hepa Thera HT-101 clinical trial makes breakthrough progress!
In the field of hepatitis B treatment, Hepa Thera's HT-101 drug clinical trial has once again brought good news. The latest 48-week follow-up data revealed the drug's significant effect in reducing the levels of hepatitis B surface antigen (HBsAg), especially its astonishing performance at low doses.
According to the trial data, all subjects in the HT-101 treatment group who participated in the extension phase maintained a good reduction in HBsAg levels at 48 weeks. Particularly striking was that in the 400mg dose group, one subject achieved an undetectable level of HBsAg at 48 weeks after only two doses, realizing the clearance of HBsAg. This achievement not only demonstrates the strong efficacy of HT-101 but also highlights its great potential in achieving functional cure of hepatitis B.
As the HT-101 clinical trial progresses, we can look forward to witnessing more innovative outcomes in the treatment of hepatitis B. Please stay tuned to Hepa Thera for more updates on HT-101.
About Hepa Thera
Established in May 2021, Suzhou Hepa Thera Biopharmaceutical Co., Ltd is a biotechnology company hatched by the New Drug Fund of Health Capital, specialized in the development of innovative drugs for liver disease treatment. Based on RNA interference, antibody, fusion protein, gene editing and other technologies, Hepa Thera addresses the unmet needs in the field of liver disease treatment including hepatitis B, nonalcoholic fatty liver disease, liver fibrosis, liver cirrhosis, independent immune liver disease; it develops products in cooperation with universities, scientific research institutes and pharmaceutical companies by means of joint development, R&D contracts and licensed introduction and other modes, and is expected to develop into an innovative enterprise putting a dent in the field of liver disease treatment in China.Established in May 2021, Suzhou Hepa Thera Biotech Co., Ltd is a biotech company incubated by the New Drug Fund of Fosun Health Capital, specialized in the development of innovative drugs for liver disease treatment. Based on RNA interference, antibody, fusion protein, gene editing and other technologies, Hepa Thera addresses the unmet needs in the field of liver disease treatment including hepatitis B, nonalcoholic fatty liver disease, liver fibrosis, liver cirrhosis, independent immune liver disease; it develops products in cooperation with universities, scientific research institutes and pharmaceutical companies by means of joint development, R&D contracts and licensed introduction and other modes, and is expected to develop into an innovative enterprise putting a dent in the field of liver disease treatment in China.
Business cooperation：Yajun He +86-13716194562 bd@hepathera.com
